Short Interest in CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) Expands By 264.5%

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) was the recipient of a significant growth in short interest during the month of January. As of January 31st, there was short interest totalling 572,600 shares, a growth of 264.5% from the January 15th total of 157,100 shares. Approximately 55.1% of the company’s stock are short sold. Based on an average daily trading volume, of 1,130,000 shares, the days-to-cover ratio is currently 0.5 days.

CERo Therapeutics Trading Down 2.7 %

Shares of CERo Therapeutics stock traded down $0.05 during trading hours on Wednesday, hitting $1.80. 138,776 shares of the company’s stock traded hands, compared to its average volume of 1,017,397. CERo Therapeutics has a 12-month low of $1.70 and a 12-month high of $1,238.00. The company has a fifty day simple moving average of $5.20 and a 200-day simple moving average of $10.23.

Insider Activity

In other news, major shareholder Bioventures Opportunities G. Yk sold 8,505 shares of the business’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $11.00, for a total value of $93,555.00. Following the transaction, the insider now owns 205,333 shares in the company, valued at $2,258,663. The trade was a 3.98 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 64,300 shares of company stock worth $529,409 over the last three months. 18.00% of the stock is currently owned by insiders.

Institutional Trading of CERo Therapeutics

An institutional investor recently raised its position in CERo Therapeutics stock. Avantax Planning Partners Inc. lifted its position in CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) by 89.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,585,151 shares of the company’s stock after purchasing an additional 1,224,021 shares during the quarter. Avantax Planning Partners Inc. owned 172.00% of CERo Therapeutics worth $155,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 29.64% of the company’s stock.

CERo Therapeutics Company Profile

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.